Skip to main content
Clinical Trials/JPRN-jRCT2080220484
JPRN-jRCT2080220484UnknownPhase 3

A study to investigate the preventive effect of AG-1749 against the onset of gastric and duodenal ulcers that can be seen during long-term treatment with low dose aspirin.

Takeda Pharmaceutical Company Limited0 sites812 target enrollmentStarted: December 13, 2007Last updated:

Trial Snapshot

Phase
Phase 3
Enrollment
812

Study Overview

Brief Summary

No summary available.

Study Design

Study Type
Interventional

Eligibility Criteria

Ages
ot applicable to ot applicable (—)
Sex
All

Inclusion Criteria

  • 1) The patient was on low-dose aspirin treatment on the day when consent was obtained, and requires the long-term continuous treatment even after treatment with the investigational drug is started.
  • 2) The patient was confirmed to have a history of gastric
  • ulcer or duodenal ulcer (combined gastric and duodenal ulcer is also possible).

Exclusion Criteria

  • Not provided

Investigators

Similar Trials